Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus adalimumab in biologic-naive active psoriatic arthritis
NL-OMON45393Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in psoriatic arthritis (PsA) and plaque psoriasis comparing Ixekizumab with Adalimumab (2 arms). Primary endpoint: Simultaneous ACR50 and PASI 100 response at Week 24. Started Jan 2018; status: active, not recruiting.
02
Drugs
ixekizumabadalimumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on NL-OMON45393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45393.